Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Imatinib in Relapsed or Refractory c‑KIT or PDGFR Positive Sarcomas (Non‑GIST)
jRCT1091220003Phase 2Completed
- Sponsor
- Office of Imatinib Phase 2 Study
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Bone and soft tissue sarcoma, Ewing sarcoma, primitive neuroectodermal tumor (PNET) and 14 more, sponsored by Office of Imatinib Phase 2 Study. Primary endpoint: Objective response rate at 600 mg/day. Started Dec 2005; status: completed.
02
Drugs
03
Conditions
Bone and soft tissue sarcomaEwing sarcomaprimitive neuroectodermal tumor (PNET)synovial sarcoma (SS)neuroblastoma
Beyond the preview
Go deeper on jRCT1091220003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220003.